Dover has entered into a definitive settlement to amass Malema Engineering Corp, a US designer and manufacturer of high-precision, mission-critical flow-measurement and control devices for the biopharmaceutical, semiconductor and industrial sectors.
Image: dizain/Adobe Stock.
Malema’s products will expand Dover’s biopharma single-use production offering, which already includes Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with services in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in revenue during the full yr 2022.
When the deal closes, Malema will become part of the PSG business unit inside Dover’s Pumps & Process Solutions segment.
“We see an incredible long-term progress opportunity in the bioprocessing trade pushed by a powerful and growing pipeline of efficient novel biologic drugs, biosimilars, protein therapies, non-COVID mRNA vaccines, as properly as budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the rising adoption of more efficient single-use manufacturing processes helps a strong outlook for our offerings of single-use elements to end-customers. เกจแรงดัน believe that pairing Malema’s know-how with our present portfolio of single-use pumps for biopharma processing will greatly enhance the accuracy and value proposition of our solutions to our clients.”
“We are methodically building out our biopharma platform by way of proactive capability additions, new product growth, and opportunistic acquisitions of highly-attractive area of interest part technologies,” stated Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing expertise and further strengthens our sensor portfolio with new proprietary expertise. In addition to enticing biopharma purposes, we expect sturdy growth in the semiconductor area on the capability enlargement and re-shoring tailwinds.”
Share